
CANM
ACMN
HALIFAX 2016
CANM 2016 Annual Scientific Meeting
Réunion scientifique annuelle de l'ACMN 2016
April 21-24, 2016 / du 21 au 24 avril 2016
Westin Nova Scotian
Halifax, Nova Scotia

As of March 30, 2016

2016 – CANM
ANNUAL SCIENTIFIC CONFERENCE

The CANM Annual Scientific Meeting's main objective is to provide current information about the use of Nuclear Medicine for the treatment of patients.

This meeting is in a setting for interdisciplinary exchanges among professionals and provides excellent opportunities for participants to interact with colleagues and experts in the field. By participating in this conference, attendees can expect to evaluate new trends, technique, therapies and diagnostic procedures in Nuclear Medicine.

THURSDAY, April 21, 2016

0700-0900	**REGISTRATION** *(Breakfast on your own)*		*Commonwealth Foyer*
0800-1800	***RADIOPHARMACY COURSE***		*Commonwealth B*
	0800-0900	Introduction to Radiopharmacy *Doug Abrams & Mihaela Ginj* *Objectives:* *Upon completion of this lecture participants should be able to understand the role of radiopharmacy in nuclear medicine and the organization of a hospital radiopharmacy. Upon completion of this lecture participants should acquire a working knowledge of the regulatory requirements governing the operations of a radiopharmacy. Upon completion of this lecture participants should understand the principles of various quality control procedures employed for radiopharmaceutical testing.* *Overview of the basic science of quality control methods for radiopharmaceuticals. Radiopharmacy design and regulatory oversight (HC and CNSC). Definition, properties and development of a radiopharmaceutical.*	
	0900-0945	GMP for RP Manufacturing *Kathy Seifert* *Objectives: The participant will gain an understanding of the concept of Good Manufacturing Practices. The participant will be able to apply the concept of Good Manufacturing Practices to radiopharmaceuticals. The Participant will be able to identify the regulatory agency which requires GMP for radiopharmaceuticals.*	
	0945-1000	*Break*	
	1000-1100	Radiopharmaceutical Isotope Production *Kennedy Mang'era* *Objectives: At the end of the session, participants will be able to identify the various production technologies that provide commonly used SPECT diagnostic and therapeutic radioisotopes and describe challenges to future isotope supply. At the end of the session, participants will be able to explain the current supply-chain and practice initiatives for mitigating impact on diagnostic nuclear medicine during isotope shortages. At the end of the session, participants will be able to describe the status of major national technological initiatives for alternative (non-uranium) production of medical isotopes.*	

1100-1145	PER Production and QC – Part 1 *John Wilson* *Objectives: Practical aspects of PER labeling. Circumventing problems by design to simplify purification and enhance specific activity. Current developments to produce sufficient quantities of (non FDG) PERs for export.*
1145-1245	*Luncheon*
1245-1330	PER Production and QC – Part 2 *John Wilson* *Objectives: Practical aspects of PER labeling. Circumventing problems by design to simplify purification and enhance specific activity. Current developments to produce sufficient quantities of (non FDG) PERs for export.*
1330-1415	Technetium Radiopharmacy – Part 1 *Kennedy Mang'era/Doug Abrams* *Objectives: At the end of the session, participants will be able to review isotope generator kinetics, review the chemistry of preparation, and quality control procedures for key SPECT radiopharmaceuticals. At the end of the session, participants will be able to relate key SPECT radiopharmaceuticals to clinical usage and pharmacology. At the end of the session, participants will be able to identify and explain the key regulatory jurisdictions and requirements that apply to radiopharmaceutical products, operations and facilities.* *Overview of Tc-99m radiopharmaceutical chemistry and of Tc-99m generator kinetics. Overview of Tc-99m radiopharmaceutical pharmacology. Overview of specific Tc-99m quality control methods.*
1415-1430	*Break*
1430-1515	Technetium Radiopharmacy – Part 2 *Kennedy Mang'era/Doug Abrams* *Objectives: At the end of the session, participants will be able to review isotope generator kinetics, review the chemistry of preparation, and quality control procedures for key SPECT radiopharmaceuticals. At the end of the session, participants will be able to relate key SPECT radiopharmaceuticals to clinical usage and pharmacology. At the end of the session, participants will be able to identify and explain the key regulatory jurisdictions and requirements that apply to radiopharmaceutical products, operations and facilities.* *Overview of non-FDG F-18 positron emitting radiopharmaceuticals. Overview of Ga-68 positron emitting radiopharmaceuticals. Over-view of C-11 positron emitting radiopharmaceuticals.*
1515-1545	Cell Labelling *Mihaela Ginj* *Objectives: Upon completion of this lecture participants will be able to discuss the methods and mechanisms by which human white blood cells and platelets are radiolabelled with Tc99m or In111. Upon completion of this lecture participants will be able to discuss the methods and mechanisms by which human red blood cells are radiolabelled with Tc99m. Upon completion of this lecture participants should be able to review the advantages and disadvantages of each autologous cells radiolabelling method.*
1545-1600	*Break*

	1600-1645	Radiopharmaceutical Therapies Available in Canada *Pamela Zabel* *Objectives: Recognize properties of an "ideal" therapeutic radiopharmaceutical. Review therapeutic radiopharmaceuticals available in Canada including I-131, Y-90 Theraspheres, Radium-223, Sr-89, Lu-177 DOTATATE, I-131 MIBG. Understand that health economic analysis, multi-disciplinary teamwork & collaboration may impact clinical availability and funding.*
	1645-1730	Miscellaneous Radiopharmaceuticals (Gallium, Octreotide, etc.) *Mihaela Ginj* *Objectives: Upon completion of this lecture participants should be able to describe the basic pharmacokinetics, elimination and biodistribution for all the radiopharmaceuticals discussed. Upon completion of this lecture participants should be able to list the clinical indications for all the radiopharmaceuticals presented. Upon completion of this lecture participants should gain a working knowledge of the preparation techniques for the tracers discussed.*
	1730-1800	Radiopharmaceuticals in Commercial Phase III or IV Trials *Pamela Zabel* *Objectives: Recognize the impact of Phase III/IV trials within the development timeline of new radiopharmaceuticals. Review some radiopharmaceuticals undergoing North American commercial Phase III or IV trials including: F-18 Amyloid agents, I-123 ioflupane (DATSCAN), Lymphoseek, F-18 Flurpiridaz, I-123 MIBG (Adreview). Understand the need to collaborate and gather "impact on patient management/outcome" data for ultimate provincial funding.*
1200 -1300	**CANM BOARD OF DIRECTORS LUNCH (closed)**	*Maritime Room*
1300 -1700	**CANM BOARD OF DIRECTORS MEETING (closed)**	*Maritime Room*
1500 -1800	**EXHIBITS AND POSTERS SET-UP**	*Commonwealth A & Atlantic Foyer*
1800-1900	**REGISTRATION & WELCOME RECEPTION with the Exhibitors**	*Commonwealth A*

FRIDAY, April 22, 2016

0700 - 1700	**REGISTRATION & EXHIBITS OPEN**	*Commonwealth Foyer & Commonwealth A*
0700 - 0730	***CONTINENTAL BREAKFAST***	*Commonwealth A & Atlantic Ballroom*
0730 - 0745	**OPENING REMARKS** ANDREW ROSS, STEVEN BURRELL, JEAN-LUC URBAIN, JONATHAN BOWER & NICHOLE SMITH	*Atlantic Ballroom*
0745-0815	**KEYNOTE ADDRESS** **Chair: Andrew Ross** Dr. Peter W. Vaughan. Deputy Minister, Nova Scotia Dept. of Health Title: Aging Population & Innovation *Objectives: Better understanding of rapid changes related to aging population needs & technological advances in the life sciences. Better*	*Atlantic Ballroom*

understand the Nova Scotia Health Innovation Strategy. Better understanding of Health Innovation in Atlantic Canada & Pan-Canadian context.

0815 -1200 **SESSION 1 (& Technologists' Program) – LUNG CANCER** *Atlantic Ballroom*

Chairs: Steven Burrell & Drew Bethune

Session's Objectives: Participants will learn clinical and imaging aspects of lung cancer from a multi-disciplinary team of oncologists, pathologists, and imaging specialists. Imaging discussions will emphasize the complementary role of CT and PET in lung cancer patient management.

0815-0845 **Oncology**
Stephanie Snow
Objectives: Review current lung cancer epidemiology. Describe current role of the Medical Oncologist in treating lung cancer. Become familiar with future trends in treating lung cancer.

0845-0915 **Pathology**
Mathieu Castonguay
Objectives: Histologically distinguish the main types of lung cancer. List non-neoplastic pulmonary lesions that may be metabolically active on PET scan. Explain why certain forms of lung cancer show variable degrees of metabolic activity.

0915-0945 **Radiation Oncology**
Liam Mulroy
Objectives: Understand the role of radiotherapy in curative treatment for early stage non-small cell lung cancer, and challenges associated with imaging following stereotactic radiotherapy. Understand the role of radiotherapy combined with chemotherapy in curative treatment of stage III non-small cell lung cancer. Understand the emerging role of radiotherapy in the treatment of patients with oligometastatic non-small cell lung cancer.

0945-1015 *Refreshment Break*

1015-1045 **Surgical**
Drew Bethune
Objective: Participants will have a better understanding of surgical decision-making influenced by imaging.

1045-1115 **CT of Lung Cancer**
Daria Manos
Objectives: Understand the role and limitations of CT in the characterization of lung nodules, including screen-detected lung nodules. Use CT in collaboration with PET and identify CT features that can strengthen or weaken the predictive value of PET for the diagnosis of lung cancer. Avoid common pitfalls in CT staging for lung cancer.

1115-1200 **PET**
Steven Burrell
Objectives: Participants will understand the presentation of different types of lung cancer on PET scans, and the role of PET scanning in the work-up of pulmonary nodules. Participants will understand the role of PET in locoregional and distal staging of lung cancers.

1200 -1300 ***LUNCHEON*** *Commonwealth A*

1300 -1600 **SESSION 2 –PEDIATRIC NUCLEAR MEDICINE** *Atlantic Ballroom*

Chairs: Raymond Lambert & Amer Shammas

Session's Objectives: Participants will learn about common, and some more unique, aspects of nuclear medicine imaging in pediatrics, including oncology. Participants will also learn about dose reduction in pediatric nuclear medicine imaging including SPECT-CT.

1300-1340 **Dose Optimization in Pediatric Nuclear Medicine**
Frederic Fahey
Objectives: List 3 factors that affect radiation dose in children. Describe 3 ways to optimize administered activity in pediatric nuclear medicine. List 2 standards available for administered activities in children.

1340-1410 **Pediatric Urology: The Clinician's Perspective**
Peter Anderson
Objectives: Differentiate which patients benefit from the diagnosis of vesicoureteral reflux. Identify the clinical scenarios when a renal cortical scan helps in the management of urinary infection. Provide the information the clinician needs when assessing congenital hydronephrosis.

1410-1450 **General Pediatric NM- Read with the Expert**
Raymond Lambert
Objectives: Describe the particularities of pediatric imaging in nuclear medicine. Review pediatric cases for current general practice in nuclear medicine.

1450-1520 *Refreshment Break*

1520-1600 **Nuclear Medicine in Pediatric Oncology**
Amer Shammas
Objectives: Describe the Nuclear imaging in pediatric Lymphoma. Describe the Nuclear imaging in pediatric Sarcomas. Describe the Nuclear imaging in pediatric Neuroblastoma and MIBG Therapy.

1300-1645 **SESSION 3- Technologists' Program – RADIOPHARMACY** *Commonwealth B*

Chairs: Jonathan Bower & Nichole Smith

Session's Objectives: Participants will learn about a variety of topical radiopharmacy issues, including issues dealing with impending ^{99m}Tc shortages and issues around production of positron emitting radiopharmaceuticals.

1300-1340 **International Isotope Supply**
François Couillard
Objectives: Understand the global supply chain of Tc-99m. Assess the impact of the impending closure of the NRU reactor. Assess the state of development of new technologies to produce Tc-99m.

	1340-1410	**99mTc: Alternate Methods of Production** Kennedy Mang'era *Objectives: At the end of the session, participants will be able to review the rationales for the dominant utilization of Tc99m in nuclear medicine and the various Tc99m radiopharmaceuticals. At the end of the session, participants will be able to review the current production processes for Tc99m production and challenges to Tc99m supply. At the end of the session, participants will be able to describe the status of major initiatives for alternative (non-uranium) production technologies for medical isotopes and initiatives for mitigating impact on diagnostic nuclear medicine during isotope shortages.*
	1410-1440	*Break*
	1440-1520	**GMP** Kathy Seifert *Objectives: The participant will gain an understanding of the concept of Good Manufacturing Practices. The participant will be able to apply the concept of Good Manufacturing Practices to radiopharmaceuticals. The Participant will be able to identify the regulatory agency which requires GMP for radiopharmaceuticals.*
	1520-1600	**Cell Labelling** Mihaela Ginj *Objectives: Upon completion of this lecture participants will be able to discuss the methods and mechanisms by which human white blood cells and platelets are radiolabelled with Tc99m or In111. Upon completion of this lecture participants will be able to discuss the methods and mechanisms by which human red blood cells are radiolabelled with Tc99m. Upon completion of this lecture participants should be able to review the advantages and disadvantages of each autologous cells radiolabelling method.*
	1600-1645	**PET/PER** John Wilson *Objectives: Practical aspects of PER labeling. Circumventing problems by design to simplify purification and enhance specific activity. Current developments to produce sufficient quantities of (non FDG) PERs for export.*

1600- 1635 **AWARD and ABSTRACT PRESENTATIONS** *Atlantic Ballroom*

Chairs: Jean-Luc Urbain & Steven Burrell

ERIC LEPP COMPETITION WINNER PRESENTATION

1600- 1607 Aberrant Auditory Cortex Activity on Brain FDG-PET Prompts Clinical Audit of Sound Levels in the Uptake Facilities at a University Hospital Site – *Hector Aguilar (EL-001)*

SELECTED ABSTRACT ORAL PRESENTATIONS

1607-1614 Reproducibility of Sentinel Node Lymphoscintigraphy in Patients with Melanoma – *Mohammad Golfam (005)*

1614-1621 Scintigraphic Assessment of Cardiac Implantable Electronic Device Infection: A Systematic Review - *Mohammad Golfam (006)*

1621-1628 Timing of Hormone Withdrawal In Children Undergoing I131 Whole Body Scan (WBS) for Thyroid Cancer – *Raymond Lambert (002)*

1628-1635 The Striatal Dissociation Between Resting State FDG PET and Perfusion MRI in Parkinson's Patients Receiving Levodopa – *Maram Aljuaid (011)*

1635-1700	***Libations amongst the Posters***	*Atlantic Foyer*
1700-1800	**CANM AGM**	*Atlantic Ballroom*
1800 - ON	**FREE EVENING**	

SATURDAY, April 23, 2016

0700 - 0730	**Run with the President (5 km along the waterfront)**	*Meet in Hotel Lobby*
0745 - 1700	**REGISTRATION**	*Commonwealth Foyer*
0745 - 0830	***CONTINENTAL BREAKFAST***	*Commonwealth A*
0745 - 1700	**EXHIBITS CONTINUE**	*Commonwealth A*

0830 - 1230 **SESSION 4 – THE FUTURE OF NUCLEAR MEDICINE** — *Atlantic Ballroom*

Chairs: Jean-Luc Urbain & Andrew Ross

Session's Objectives: Participants will hear and participate in broad discussions on the future of nuclear medicine from a group of international experts and from Health Canada, as well as the future of RCPSC training of Canadian nuclear medicine residents.

0830-1000 **Presentations from International Experts**

Patrick Bourguet (France), Fernando Mut (Uruguay), S.E. François Couillard (CAMRT), Jean-Philippe Vuillez (France), Sanjay Gambhir (India), Sally Schwarz (SNMMI)

Objectives:

Patrick Bourguet: Compare the European and Canadian health system. Compare the practice in nuclear medicine between Europe and Canada. Compare the organization of nuclear medicine departments between Europe and Canada.

François Couillard: Understand global trends affecting nuclear medicine from a technology and "business" perspective. Anticipate the impact of these trends on nuclear medicine departments. Help nuclear medicine professionals adapt to a fast changing environment.

Sanjay Gambhir: Growth of Nuclear Medicine in India. Impetus to radionuclide therapy. Integration of Hybrid Imaging.

Fernando Mut: To learn about some recent developments in hybrid molecular imaging instrumentation. To learn about some recent radiopharmaceuticals and proper use of clinical applications in neurology, cardiology and oncology. To learn about practical use of some novel radiopharmaceuticals for treatment purposes.

Sally Schwarz: Future production of medical isotopes, primarily Tc-99m. Impact of regulatory requirements on radiopharmaceuticals. Future direction

Jean-Philippe Vuillez: Give participants an overview of the material and human resources of the practice of nuclear medicine in France. Give participants an overview of preclinical and clinical research activity in nuclear medicine in France. Give participants an overview of the nuclear medicine

activities in France (type and number of examinations).

1000-1030	*Refreshment Break*
1030-1130	**Roundtable Discussion**
1130-1200	**Health Canada** Anthony Ridgway *Objectives: At the end of this lecture, the learner will be able to explain the main elements of the regulatory process for Schedule 'C' drugs. At the end of this lecture, the learner will be able to discuss ongoing and planned regulatory changes affecting Schedule 'C' drugs.*
1200-1230	**Royal College- Nuclear Medicine Training** David Barnes *Objectives: Participants will improve their understanding regarding the current Royal College requirements and opportunities for training in Canada. Participants will increase their knowledge of training requirements in other countries. Participants will have a better understanding of concepts and impact of Competency by Design on the future training of Nuclear Medicine Specialists.*

0830- 1230 **SESSION 5-Technologists' Program – Breast Cancer** *Commonwealth B*

Chairs: Jonathan Bower & Nichole Smith

Session's Objectives: Participants will learn clinical and imaging issues in breast cancer as they pertain to the nuclear medicine technologist, including an interactive workshop on performing sentinel node procedures.

0830-0915	**Breast Cancer: Oncology** Daniel Rayson *Objectives: To illustrate new developments in targeted breast cancer therapy. To understand the spectrum of individualized breast cancer treatment. To understand the goals and outcomes of state of the art breast cancer care.*
0915-1000	**The Role of Nuclear Medicine in Breast Cancer** Daniel Levin *Objectives: To identify Nuclear Medicine examinations which can be useful in evaluating patients with breast cancer. To understand how to tailor examinations for optimal patient care.*
1000-1030	*Refreshment Break*
1030-1115	**Revisiting Wall Motions: A Technical Refresher** Nichole Smith *Objectives: Ability to critically analyze Wall Motion studies and technical processing. Understand the current Wall Motion processing techniques and be able to discuss the resulting quantitative values. Be able to discuss common variances that arise in the clinical setting and how to properly address them.*

	1115-1200	**The Utility of Pre-Operative Lymphatic Mapping in Breast Cancer** Sian Iles *Objectives: At the end of this session, participants will be able to describe the importance of sentinel node mapping in the staging of breast cancer. At the end of the session participants will be able to describe several different approaches for sentinel node injection and their advantages and disadvantages. At the end of the session participants will be able to describe three causes of false negative sentinel node studies.*
	1200-1230	**Sentinel Node Breast Injections: An Interactive Workshop** Sian Iles *Objectives: At the end of the session participants will be able to describe several different approaches for sentinel node injection and their advantages and disadvantages. At the end of the session participants will be able to list at least 2 situations when a periareolar injection is not the best approach for sentinel node mapping. At the end of the session participants will be able to describe the steps for performing a perioareolar breast injection for sentinel node mapping and perform a periareolar inject with skin boost.*

1230 - 1330	***LUNCHEON***	*Commonwealth A*

1230 - 1400	**SPECIALTY COMMITTEE MEETING (closed)**	*Maritime Room*

1330 - 1700	**SESSION 6 – RADIOISOTOPE THERAPY** **Chairs: Sandy McEwan & Daniel Rayson** *Session's Objectives: Participants will learn about the current status of radioisotope therapy, from latest updates on established therapies to emerging therapies entering clinical practice across Canada.*	*Atlantic Ballroom*

	1330-1400	**Changing Paradigms in Cancer Therapy** Daniel Rayson
	1400-1430	**Radium-223 for Bone Mets** Ravi Mohan *Objectives: Participants will be able understand the basic principles of Radium 223 Therapy. Participants will be able to understand some of the challenges in implementing a Radium 223 Program.*
	1430-1500	**Ga-68 PET Imaging of NET's** Sandy McEwan
	1500-1530	**NET Therapy (MIBG and Lutetium)** Sandy McEwan
	1530-1600	*Refreshment Break*
	1600-1630	**Y90 Microspheres** Rob Berry *Objectives: Present the indications for Y90 radioembolization. Describe the appropriate Y-90 work up prior to therapy. Review outcomes of Y-90 therapy.*

1630-1700	**Thyroid Cancer: What's New?** Murali Rajaraman *Objectives: Describe the major trends in thyroid cancer epidemiology and patterns of care and be aware of the changes in recently updated management guidelines. Identify the points along the thyroid cancer care path where dynamic risk stratification should be employed and cite the evidence supporting active surveillance protocols. Recognize strategies that can help address the challenges facing thyroid cancer care professionals and patients in Canada.*	

1330 - 1800	**SESSION 7- Technologists' Program – SPECT/CT** **Chairs: Jonathan Bower & Nichole Smith** *Session's Objectives: SPECT-CT imaging has emerged as a keystone of nuclear medicine departments. Participants will learn about important aspects of SPECT-CT including clinical applications, technical aspects, and patient dose reduction.*	*Commonwealth B*
1330-1400	**The Clinical Impact of SPECT/CT** Ash Wiley *Objectives: To review the value SPECT-CT adds to the interpretation of nuclear medicine examinations over planar imaging alone. To review how the information garnered from SPECT/CT affects patient management.*	
1400-1440	**CT Within Hybrid Imaging – Dosimetry and Communicating with Patients** Frederic Fahey	
1440-1500	*Refreshment Break*	
1500-1540	**Attenuation Correction in Myocardial Perfusion Imaging** Jennifer Sperry *Objectives: To Review with Technologists how Attenuation Correction is applied to images. To identify possible pitfalls that could create areas of concern with image interpretation. To identify the advantages of Attenuation correction.*	
1540-1620	**SPECT/CT Interesting Cases** Jeremy Jackson & Jonathan Bower *Objectives:* *Jeremy Jackson: To identify 3 ways in which SPECT/CT may benefit an infection imaging study. To recognize how alterations in time delay before scanning, may help or hinder a study in infection imaging.* *Jonathan Bower: By the end of this presentation the learners will be able to interpret non-conventional patterns of radiopharmaceutical bio distribution through the assistance of hybrid CT imaging. Learners will be able to correlate the need for anatomical imaging, using hybrid CT, with stand alone nuclear medicine images. During the presentation learners will be able to apply clinical and theoretical knowledge to aid in the interpretation of nuclear medicine SPECT/CT images.*	

	1620-1700	**SPECT/CT Bone Scanning of the Feet: Impact on Orthopedic Surgical Intervention** Mark Glazebrook *Objectives: Learn how CT spec are used in Orthopedics. Understand CT spec uses in Orthopedic F&A Research. See examples of CT Spec assisting F&A Orthopedic Diagnosis.*
	1700-1800	***Reception for technologists, sponsored by the CAMRT***

1800 -2200 **CANM RECEPTION, ANNUAL DINNER & AWARDS AT PIER 21**

1800-1900 **Reception in Rudolph P. Bratty Hall at the Canadian Museum of Immigration at Pier 21**

Grab a glass of wine and experience the immigration journey with the museum tour guides.

You can research your ancestors' journey in advance; see the request information form from the Museum on the CANM website, click here; it's free.

1900-2200 **Lobster Dinner in Kenneth Rowe Hall**

Do not miss this typical maritime lobster dinner with all the trimmings; you do not like lobster? We can provide you with an alternative dinner (BBQ Chicken or vegetarian meal) if you let us know well in advance.

2016 CANM Emeritus Member – Dr. Douglas Abrams

Please celebrate with us Dr. Abrams accomplishments.

SUNDAY, April 24, 2016

0830 - 0900	**REGISTRATION**	*Commonwealth Foyer*
0830 - 0900	***CONTINENTAL BREAKFAST***	*Commonwealth A*
0830 - 1030	**EXHIBITS CONTINUE**	*Commonwealth A*
0830 - 0900	**BUCH RADIOPHARMACEUTICAL DEVELOPMENT FOR ALZHEIMERS** Sultan Darvesh *Objectives: Current neuroimaging techniques for Alzheimer diagnosis. Limitations of current neuroimaging techniques for Alzheimer diagnosis. Molecular imaging in Alzheimer diagnosis.*	*Atlantic Ballroom*
0900 - 1230	**SESSION 8 – CARDIAC** **Chairs: Jean-Luc Urbain & Marcelo Di Carli** *Session's Objectives: Participants will learn about the current state of the art in cardiac nuclear medicine, including myocardial perfusion imaging with PET and CZT SPECT cameras, viability imaging, and the role of cardiac CT and MRI imaging.*	*Atlantic Ballroom*

0900-0930 **Read with the Expert- Cardiac Cases**

Jean-Luc Urbain

Objectives: Review the risk stratification for cardio-vascular diseases. Practice the integrated interpretation of nuclear cardiology images. Test the ability to render a quick interpretation of a nuclear cardiology study.

0930-1000	**Future of MPI 1: PET** Marcelo Di Carli *Objectives: To review new evidence about the role of quantitative perfusion imaging in diagnosis and management of CAD.*
1000-1030	**Future of MPI 2: SPECT with CZT** Glenn Wells *Objectives: Participants will learn what are the differences between current NaI cameras and cardiac CZT cameras. Participants will learn how the CZT cameras can improve MPI with SPECT. Participants will learn how CZT cameras can be used for dynamic imaging and measurement of absolute myocardial blood flow.*
1030-1100	**Cardiac PET with FDG: Viability and Inflammation Imaging** Marcelo Di Carli *Objectives: To discuss the role of viability imaging in management of CAD. To review emerging role of FDG in assessing myocardial inflammation.*
1100-1130	*Refreshment Break*
1130-1200	**MPI and CCTA: Complementary or Redundant?** Sanjay Gambhir *Objectives*: *Is there a case for Hybrid MPI and CACT. Its present status. Radiation Safety and Future directions.*
1200-1230	**Cardiac MRI and CT for the Nuclear Medicine Physician** James Clarke *Objectives: Participants will know the indications and contraindications for Cardiac MRI and CT studies. Participants will know some benefits and limitations of Cardiac MRI and CT examinations.*

1230	**CLOSURE – END OF MEETING** Steven Burrell & Andrew Ross	*Commonwealth A*

MAINTENANCE OF CERTIFICATION

This event is an accredited group learning activity as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada for Section 1 activities and approved by the Canadian Association of Nuclear Medicine and the Canadian Association of Medical Radiation Technologists (CAMRT)

La présente activité, approuvée par l'Association canadienne de médecine nucléaire pour la section 1 et par l'Association canadienne des technologues en radiation médicale constitue une activité de formation collective agréée conformément à la définition précisée dans le programme de Maintien du certificat du Collège royal des médecins et chirurgiens du Canada.

2015-2016 CANM BOARD OF DIRECTORS

As of March 30, 2016

SCIENTIFIC PROGRAM COMMITTEE - 2016

Dr. Jean-Luc Urbain, Co-Chair
Dr. Steven Burrell, Co-Chair
Mr. Jonathan Bower, Co-Chair
Ms. Nichole Smith, Co-Chair
Dr. Doug Abrams
Dr. Andrew Ross
Dr. Khun Visith Keu
Mr. Pierre Prévost
Ms. Jodie Piercey

CONTACT US

For information, please visit our Website at:
http:/canm-acmn.ca

CANM Office Tel: 613-882-5097
E-mail: canm@canm-acmn.ca